GlycoNex Incorporation Sustainability Reports
GlycoNex Inc. is a clinical-stage biotechnology company focused on the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies. The company's pipeline includes antibody-drug conjugates (ADCs) and biosimilars for cancer therapy and osteoporosis treatments.
Sector: Manufacturing
Country: Taiwan
Exchange: Taipei Exchange
FIGI: BBG002B3T7K7
9 reports from 2014 to 2025
